Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

Inclusion Criteria: * Subject is willing and able to provide informed consent for study participation. * Subject is ≥ 18 years of age. * Subject has an established diagnosis of T1D or T2D as determined by medical evaluation at screen. * Subjects A1c \<9.8% * Subject is clinically stable with respect to underlying renal impairment and diabetes, as assessed by the Investigator's medical evaluation. * Subject has been diagnosed with Stage 3 CKD as defined by eGFR (MDRD) between 30 - \<60 or Stage 4 as defined by eGFR \<30 (not on dialysis) at screening. * Subject has a body mass index (BMI) between 18 to 45 kg/m2 (inclusive). Exclusion Criteria: * Subject has positive drug test for drugs of abuse and/or positive alcohol breath test at screening and Day 0. * Subject is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits. * Subject has a history of significant allergic diathesis such as urticaria, angioedema, or anaphylaxis. * Subject has had any live vaccination ≤ 3 months prior to enrollment or will require vaccination during the study. * Subject must not be taking an ACEi medication for 5 half-lives prior to study drug administration and for 5 days post study drug administration. * Subject is unwilling or unable to limit smoking to ≤ 10 cigarettes per day (or other products that contain nicotine limited to \< 200 mg of nicotine/day) during the study participation period. * Subject has a current malignancy or active mal…